First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration

2024/09/16 by J. Rodon, Jordi Rodón, Hans Prenen +33 · 1 voice · 3 citations
Biochemistry, Genetics and Molecular Biology · #Cancer-related gene regulation #Polyamine Metabolism and Applications #Virus-based gene therapy research

paper · pdf · doi:10.1016/j.annonc.2024.08.2339

openalex publication_date 2024/09/16 · openalex created_date 2024/09/20 · openalex updated_date 2026/07/31

Cited by

• MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies
• Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies
• Capturing Unicorns: Targeting Cancers With <i>TP53</i> Mutations, <i>RAS</i> Alterations Beyond G12C, and <i>MTAP</i> Loss—No Target Is Out of the Realm of Possibility

Discussions

• First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in MTAP-deleted solid tumors @Annals_Oncology doi.org/10.1016/j.an... 🔎 phs I 👉ORR 21.4% across 8 tumor types 👉favorable safety [bsky, 2 points, 0 comments]